Observed OS in patients from the training series compared with the expected OS in the matched general population. OS in CLL patients stratified according to the FISH cytogenetic model (A) and the integrated mutational and cytogenetic model (B) relative to the expected OS in the age-, sex-, and calendar year of diagnosis–matched general population (black line). (A) Patients harboring del17p13 irrespective of cooccurring cytogenetic lesions are represented by the red line. Patients harboring del11q22-q23 in the absence of del17p13 are represented by the purple line. Patients harboring +12 in the absence of del17p13 and del11q22-q23 are represented by the yellow line. Patients harboring a normal FISH karyotype are represented by the green line. Patients harboring del13q14 deletion in the absence of other cytogenetic abnormalities are represented by the blue line. (B) Patients harboring TP53 and/or BIRC3 disruption (TP53 DIS/BIRC3 DIS) independent of cooccurring genetic lesions are represented by the red line. Patients harboring NOTCH1 mutations (NOTCH1 M) and/or SF3B1 mutations (SF3B1 M) and/or del11q22-q23 in the absence of TP53 and BIRC3 disruption are represented by the yellow line. Patients harboring +12 in the absence of TP53 disruption, BIRC3 disruption, NOTCH1 mutations, SF3B1 mutations, and del11q22-q23, and patients wild-type for all genetic lesions (normal) are represented by the green line. Patients harboring del13q14 as the sole genetic lesion are represented by the blue line.